Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUP TSE:CARA CVE:PYR NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara OperationsC$0.00C$21.20▼C$29.88C$1.62BN/A36,321 shs35,304 shsPYRPyroGenesis Canada Inc. (PYR.V)C$3.85+11.0%C$3.85C$0.19▼C$6.43C$606.96MN/A337,985 shs335,425 shsSLSSELLAS Life Sciences Group$14.98$8.11$1.39▼$15.88$2.95B2.4210.33 million shs17.22 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Operations0.00%0.00%0.00%0.00%0.00%PYRPyroGenesis Canada Inc. (PYR.V)0.00%0.00%0.00%0.00%0.00%SLSSELLAS Life Sciences Group0.00%+20.90%+65.71%+262.71%+606.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara OperationsC$0.00C$21.20▼C$29.88C$1.62BN/A36,321 shs35,304 shsPYRPyroGenesis Canada Inc. (PYR.V)C$3.85+11.0%C$3.85C$0.19▼C$6.43C$606.96MN/A337,985 shs335,425 shsSLSSELLAS Life Sciences Group$14.98$8.11$1.39▼$15.88$2.95B2.4210.33 million shs17.22 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Operations0.00%0.00%0.00%0.00%0.00%PYRPyroGenesis Canada Inc. (PYR.V)0.00%0.00%0.00%0.00%0.00%SLSSELLAS Life Sciences Group0.00%+20.90%+65.71%+262.71%+606.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ACARACara Operations 0.00N/AN/AN/APYRPyroGenesis Canada Inc. (PYR.V) 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 2.00Hold$10.00-33.24% DownsideCurrent Analyst Ratings BreakdownLatest PYR, AUP, SLS, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00CARACara OperationsN/AN/AN/AN/AN/AN/APYRPyroGenesis Canada Inc. (PYR.V)C$6.01M100.97C$0.01 per share294.62C$0.02 per share183.33SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ACARACara OperationsN/AN/AN/AN/AN/AN/AN/AN/AN/APYRPyroGenesis Canada Inc. (PYR.V)N/A-C$0.03N/AN/AN/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest PYR, AUP, SLS, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ACARACara OperationsC$0.411.54%N/AN/AN/APYRPyroGenesis Canada Inc. (PYR.V)N/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02CARACara OperationsN/AN/AN/APYRPyroGenesis Canada Inc. (PYR.V)165.500.320.32SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ACARACara OperationsN/APYRPyroGenesis Canada Inc. (PYR.V)N/ASLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ACARACara OperationsN/APYRPyroGenesis Canada Inc. (PYR.V)N/ASLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableCARACara Operations8058.57 millionN/ANot OptionablePYRPyroGenesis Canada Inc. (PYR.V)90157.65 millionN/ANot OptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionablePYR, AUP, SLS, and CARA HeadlinesRecent News About These CompaniesMost and least shorted mid- to mega-cap healthcare stocks at the end of JuneJuly 1, 2026 | seekingalpha.comSELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial DataJuly 1, 2026 | finance.yahoo.comSELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 52-Week High - Should You Buy?July 1, 2026 | americanbankingnews.comDoes SELLAS (SLS) Executive Severance Reset Hint at M&A Readiness or Standalone Ambition?June 30, 2026 | uk.finance.yahoo.comWhy Sellas Remains A Strong Sell After Doubling In PriceJune 30, 2026 | seekingalpha.comSELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?June 30, 2026 | benzinga.comSellas Life (SLS) Climbs to Record High on Acquisition BuzzJune 30, 2026 | finance.yahoo.comSellas Life Sciences shares break out to new 52-week high: What's driving the momentum?June 29, 2026 | msn.comIs SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?June 29, 2026 | insidermonkey.comWhy did SLS, MRNA, ABCL stocks surge to 52-week highs last week?June 28, 2026 | msn.comSellas Life Sciences: The AML Platform Is More Interesting Than The Binary EventJune 27, 2026 | seekingalpha.comSELLAS Life Sciences jumps as traders focus on imminent REGAL trial catalyst and stronger cash positionJune 26, 2026 | quiverquant.comQSELLAS stock hits new highs: What's happening today?June 26, 2026 | msn.comWhat's driving SLS stock higher today and what comes next?June 26, 2026 | invezz.comISLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout ChatterJune 26, 2026 | finance.yahoo.comSellas (SLS) Extends Rally, New Filing Hints at Company TakeoverJune 26, 2026 | insidermonkey.comSLS stock up 13% as executive severance updates reignite buyout speculationJune 25, 2026 | msn.comSLS stock slips overnight: Shareholders approve 20M new shares, CEO awarded 1M RSUsJune 22, 2026 | msn.comWhat Does Strong Shareholder Support Mean for SELLAS Life Sciences Group (NASDAQ:SLS)?June 19, 2026 | kalkinemedia.comKSELLAS Stockholders Approve Governance and Equity Plan ChangesJune 18, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYR, AUP, SLS, and CARA Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Cara Operations TSE:CARACara Operations Limited operates and franchises full service restaurants. It operates through four segments: Corporate Restaurants, Franchise Restaurants, Food Processing and Distribution, and central operations. As of December 31, 2017, the company operated 1,272 restaurants, including 1,221 restaurants in Canada and 51 locations internationally under the Swiss Chalet, Harvey's, St-Hubert, Milestones, Montana's, Kelsey's, East Side Mario's, New York Fries, Prime Pubs, Bier Markt, Landing, Original Joe's, State & Main, Elephant & Castle, Burger's Priest, Pickle Barrel, Taverne Moderne, and The Keg restaurant brands. Cara Operations Limited was founded in 1883 and is headquartered in Vaughan, Canada.PyroGenesis Canada Inc. (PYR.V) CVE:PYRC$3.85 +0.38 (+10.95%) As of 11/19/2020PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes advanced plasma processes and systems in Canada and internationally. It offers DROSRITE, a sustainable process for enhancing metal recovery from dross targeting primarily metallurgical industry; plasma atomized metal powders; PUREVAP, a process to produce high purity metallurgical grade silicon and solar grade silicon from quartz; plasma fired steam generator, which directly generates steam suitable for steam-assisted gravity drainage (SAGD) for the oil and gas industry; and custom reactors and furnaces for use in advanced materials, metallurgical, environmental, and chemical fields. The company also provides plasma torches, including APT for waste treatment, gas heating, research and development, and advanced materials production applications; Minigun, which offers a solution for thermal treatment of metals, nanotechnology, and material fabrication; reverse polarity torches for use in the production of high purity materials and nanomaterials, research and development, waste treatment, and thermal spray coatings; and SPT plasma torches for use in the destruction of refrigerants and other substances. In addition, it offers plasma arc gasification and vitrification system; plasma arc waste destruction system for land; plasma arc waste destruction system; PRRS, a plasma waste-to-energy solution; SPARC, a process for the destruction of ozone depleting substances and other environmentally noxious chemicals; and tactical PACWADS system that destroys chemical warfare agents. The company serves defense, metallurgical, mining, advanced materials, oil and gas, and environmental industries. PyroGenesis Canada Inc. is based in Montréal, Canada.SELLAS Life Sciences Group NASDAQ:SLS$14.98 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$14.81 -0.17 (-1.13%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
